Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Reverse split

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Apr 03, 2021 9:29am

225 Views

Post# 32933504

RE:Reverse split

If you think the stock price will go to 1$ without RS, then with RS it will go to 2$ (taking your example of 1:2 RS as guidance) and probably even higher, as there are less shares in circulation. In the end you will have >500k$. However, this positive RS scenario will only work if there are well received PR's coincide with the RS. If that's not the case, then the stock will be shorted and you will end with a loss

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo